INOVIO Reports Q2 2026 Results; FDA Review of INO-3107 Advances Toward October 30 PDUFA

summarizeSummary

INOVIO reported Q2 2026 results with a narrowed net loss and provided key regulatory updates: FDA review of INO-3107 is advancing toward an October 30 PDUFA date, and partner ApolloBio reported positive Phase 3 data for VGX-3100 in China.

check_boxKey Events · Earnings and Guidance · INO

• FDA Review Advances for INO-3107

  Late-cycle review meeting and all scheduled pre-licensure inspections completed; informal clinical meeting held. PDUFA target action date remains October 30, 2026.

• Positive Phase 3 Data for VGX-3100

  Partner ApolloBio reported positive topline results from its pivotal Phase 3 trial of VGX-3100 for cervical dysplasia in China, meeting the primary efficacy endpoint.

• Commercial Launch Preparations Underway

  Engaged Syneos Health for MSL deployment and as contract sales organization; identified third-party logistics, specialty pharmacy, and patient hub partners.

• Q2 Net Loss Narrows on Non-Cash Gain

  Net loss of $6.0M vs $23.5M in Q2 2025, driven by a $13.9M non-cash gain from warrant liability fair value adjustment. R&D expenses decreased to $10.8M from $14.5M.

auto_awesomeAnalysis · INO · Life Sciences

INOVIO's Q2 2026 earnings release provides critical updates on its lead asset INO-3107, including completion of late-cycle review and pre-licensure inspections, and an informal FDA meeting. The company also disclosed positive Phase 3 data from its partner ApolloBio for VGX-3100 in China and detailed commercial launch preparations. Financially, the net loss narrowed significantly due to a non-cash warrant liability gain, but cash runway remains tight into late Q1 2027, underscoring the importance of the upcoming PDUFA decision.